Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Acumen Pharmaceuticals, Inc. (ABOS : NSDQ)

• Company Description    Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The company's product pipeline consist ACU193. Acumen Pharmaceuticals Inc. is based in CHARLOTTESVILLE, Va. Number of Employees: 61

• Price / Volume Information    Yesterday's Closing Price: $2.13 Daily Weekly Monthly 20 Day Moving Average: 639,258 shares Shares Outstanding: 72.23 (millions) Market Capitalization: $153.85 (millions) Beta: 0.34 52 Week High: $3.60 52 Week Low: $1.19 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.62% -4.33% 12 Week -10.88% -13.32% Year To Date 0.95% -4.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1210-1220 WASHINGTON ST. SUITE 210 - Newton,MA 02465 USA ph: 617-344-4190 fax: - abraun@acumenpharm.com http://www.acumenpharm.com

• General Corporate Information    Officers Daniel O'Connell - Chief Executive Officer William Matthew Zuga - Chief Financial Officer and Chief Business Officer Kimberlee C. Drapkin - Director Sean Stalfort - Director Jeffrey L. Ives - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00509G209 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 72.23 Most Recent Split Date: (:1) Beta: 0.34 Market Capitalization: $153.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.39 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.39 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 4.72% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.76 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 31.25% vs. Previous Quarter: 19.51% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -123.07 12/31/25 - -111.26 ROA 06/30/26 - - 03/31/26 - -79.41 12/31/25 - -75.67 Current Ratio 06/30/26 - - 03/31/26 - 4.55 12/31/25 - 4.07 Quick Ratio 06/30/26 - - 03/31/26 - 4.55 12/31/25 - 4.07 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 1.21 12/31/25 - 1.16 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.19 12/31/25 - 0.32 Debt-to-Capital 06/30/26 - - 03/31/26 - 16.21 12/31/25 - 24.13

Powered by Zacks Investment Research ©